Research Progress of Targeted Therapy for HER2 Gene
in Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.101.49
- Author:
Lingping KONG
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Antibody-drug conjugate;
Human epidermal growth factor receptor-2;
Lung neoplasms;
Tyrosine kinase inhibitor
- From:
Chinese Journal of Lung Cancer
2020;23(12):1108-1112
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common malignancy tumor. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer. Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor in ERBB/HER family, which activates downstream signal transduction with other family members such as epidermal growth factor receptor (EGFR). HER2 gene mutation is closely related to the progression of many epithelial cell cancers. Tumors with high expression of HER2 show strong metastasis and invasion ability, poor sensitivity to chemotherapy, and are prone to relapse. At present, lung cancer driven gene targeted therapy has made rapid progress. Although the frequency of HER2 gene mutation in NSCLC is lower than that of EGFR, its driving mechanism in lung cancer is clear and partial targeted therapy is effective, which may become a new standard treatment in the future. This review focuses on the research progress of HER2 gene mutation in the treatment of NSCLC.
.
